REBUILD-2 - I5Q-MC-CGAT( e): A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine - the REBUILD-2 Study

Grants and Contracts Details

StatusActive
Effective start/end date3/16/227/9/25

Funding

  • Eli Lilly and Company: $63,879.00